The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Disclosure of Conflicts of Interest – Prof. Ruth Plummer

This is a disclosure report regarding financial/non-financial relationships with for-profit/non-profit healthcare organizations.

Pharmaceutical companies with potential conflict of interest

  • In the last three years, honoria for attending advisory boards from Pierre Faber, Bayer, Novartis, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Immunocore, Genmab, Astex Therapeutics, Medivir, and Sanofi Aventis.
  • Honoraria for working as an IDMC member for Alligator Biosciences, GSK, Onxeo and SOTIO Biotech AGI
  • Honoraria for delivery of educational talks or chairing educational meetings by AstraZeneca, Novartis, Bayer and BMS.
  • Funds to support attendance at conferences from MSD and BMS.

Other affiliations with potential conflict of interest

  • No partnerships to disclose.


Last updated on 12 January 2022

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70